Anti-(homo Sapiens Tnfrsf4(tumor Necrosis Factor Receptor (tnfr) Superfamily Member 4 Uses, Dosage, Side Effects and more
Anti-(homo Sapiens Tnfrsf4(tumor Necrosis Factor Receptor (tnfr) Superfamily Member 4 Uses, Dosage, Side Effects, Food Interaction and all others data.
Anti-(homo Sapiens Tnfrsf4(tumor Necrosis Factor Receptor (tnfr) Superfamily Member 4 is under investigation in clinical trial NCT03029832 (A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy).
| Trade Name | Anti-(homo Sapiens Tnfrsf4(tumor Necrosis Factor Receptor (tnfr) Superfamily Member 4 |
| Generic | Vonlerolizumab |
| Vonlerolizumab Other Names | Immunoglobulin g1-kappa, anti-(homo sapiens tnfrsf4(tumor necrosis factor receptor (tnfr) superfamily member 4, act35, ox40, cd134)), humanized monoclonal antibody, Immunoglobulin g1-kappa, anti-(human tumor necrosis factor receptor superfamily member 4 (act35 antigen, ox40l receptor, cd134 antigen))humanized mouse monoclonal antibody: .gamma.1 heavy chain (1-447) (humanized mouse vh (homo sapiens ighv1-46*01 (81%), Pogalizumab, Vonlerolizumab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
